Trial Profile
A Randomized Open-label Dose-ranging, Multi-center Trial to Assess the Safety and Efficacy of NKPL66 (CaPre) in the Treatment of Mild-to-moderate Hypertriglyceridemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Omega-3 phospholipid (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Acronyms COLT
- Sponsors Acasti Pharma
- 14 Aug 2017 According to an Acasti Pharma media release, select data from this and other studies (TRIFECTA, PMRI2016-4010 and CAP13-101) will be submitted for publication in a peer-reviewed journal.
- 14 Aug 2017 Results from this study were included in an oral presentation at the International Academy of Cardiology Annual Scientific Sessions 22nd World Congress on Heart Disease (WCHD), according to an Acasti Pharma media release.
- 28 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.